Pazopanib Offers Edge for Metastatic Kidney Cancer
Drugs Show Similar Efficacy in Metastatic Kidney Cancer
(HealthDay News) -- While pazopanib and sunitinib are similarly effective in patients with metastatic renal-cell cancer, pazopanib is associated with better safety and quality of life, according to a study published in the Aug. 22 issue of the New England Journal of Medicine.
As part of a phase 3, open-label study, Robert J. Motzer, M.D., from the Memorial Sloan-Kettering Cancer Center in New York City, and colleagues randomly assigned 1,110 patients with clear-cell, metastatic renal-cell carcinoma to pazopanib (800 mg daily) or sunitinib in 6-week cycles (50 mg daily for 4 weeks, no treatment for 2 weeks) as a first-line treatment.
The researchers found that pazopanib and sunitinib offered similar progression-free survival (hazard ratio for progression, 1.05) and overall survival (hazard ratio for death, 0.91). Pazopanib treatment was associated with significantly better improvement on 11 of 14 health-related quality-of-life domains during the first 6 months of treatment.
Pazopanib treatment was associated with a greater incidence of elevated alanine aminotransferase, while sunitinib treatment was associated with a greater incidence of fatigue, hand-foot syndrome, and thrombocytopenia.
"Pazopanib and sunitinib have similar efficacy, but the safety and quality-of-life profiles favor pazopanib," Motzer and colleagues conclude.
The study was funded by GlaxoSmithKline, the manufacturer of pazopanib; several authors are employees of the company.